|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
|
Further information
|
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due it being a paediatric licence extension of published TA1002. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning medicines for children in specialised services policy.
|
| ID number |
11806
|
Project Team
| Project lead |
Danielle Lees |
Email enquiries
|
Date
|
Update
|
|
04 November 2024
|
Topic selection. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a paediatric licence extension of published TA1002. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning medicines for children in specialised services policy. |
|
21 April 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
21 April 2023
|
Topic selection. Update - error made in info |
|
19 April 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
19 April 2023
|
Topic selection. Topic information updated |
|
20 December 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic selection